Amendments to the Specification:

Please add the Sequence Listing submitted herewith as separately numbered pages 1-6.

Please delete the paragraphs on page 4, lines 1-12 and replace them with the following paragraphs:

[2] The preparation according to [1], wherein the GnRH agonist or a salt thereof is a peptide represented by the formula **(SEQ ID NO: 1)**:

5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z

[wherein Y represents a residue selected from DLeu, DAla, DTrp, DSer (tBu), D2Nal and DHis (ImBzl), and Z represents NH-C_2H_5 or Gly-NH_2]

or a salt thereof;

[3] The preparation according to [1], wherein the GnRH agonist or a salt thereof is an acetate of a peptide represented by the formula **(SEQ ID NO: 2)**:

5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C_2H_5;

Please delete the paragraph on page 9, line 21 to page 10, line 8 and replace it with the following paragraph:

As a specific example of the GnRH agonist, a physiologically active peptide represented by the general formula [I] **(SEQ ID NO: 1)**

5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z [I]

[wherein Y represents a residue selected from DLeu, DAla, DTrp, DSer (tBu), D2Nal and DHis (ImBzl) and Z represents NH-C_2H_5 or Gly-NH_2]

or a salt thereof is used. In particular, a peptide in which Y is DLeu and Z is NH-C_2H_5 or a salt thereof (i.e. a peptide represented by 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C_2H_5 **(SEQ ID NO: 2)** or a salt thereof, in particular, acetate thereof (leuprorelin acetate: manufactured by Takeda Chemical Industries, Ltd.)) is preferable.

Please delete the paragraphs on page 11, line 2 to page 13, line 5 and replace them with the following paragraphs:

In addition to the aforementioned leuprorelin (leuprorelin acetate), preferable examples of the GnRH agonist include,

(1) Goserelin **(SEQ ID NO: 3)**



(US-A-4100274, JP-A-52-136172),

(2) Buserelin **(SEQ ID NO: 4)**



(USP No. 4,024,248, German Patent No. 2438352, JP-A-51-41359),

(3) Triptorelin **(SEQ ID NO: 5)**



(US-A-4010125, JP-A-52-31073),

(4) Nafarelin **(SEQ ID NO: 6)**



(US-A-4234571, JP-A-55-164663, JP-A-63-264498, JP-A-64-25794),

(5) Histrelin **(SEQ ID NO: 7)**



(6) Deslorelin **(SEQ ID NO: 8)**



(US-A-4569967, US-A-4218439),

(7) Meterelin **(SEQ ID NO: 9)**



(PCT WO 91/18016),

(8) Gonadrelin **(SEQ ID NO: 10)**



(German Patent No. 2213737)

and salts thereof.

Please delete the paragraph on page 17, lines 16-22 and replace it with the following paragraph:

The GnRH agonist, preferably a peptide represented by the formula 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C_2H_5 **(SEQ ID NO: 2)** or a salt thereof (hereinafter, simply referred to as "leuprorelin or a salt thereof" in some cases), more preferably leuprorelin acetate is administered as a sustained-release microcapsule, more preferably as an injectable comprising the sustained-release microcapsule.

Please delete the paragraph on page 72, line 23 to page 74, line 2 and replace it with the following paragraph:

119.1 g of 5-oxo-Pro-His-Trp-Ser-Tyr-Dleu-Leu-Arg-Pro-NH-C_2H_5 **(SEQ ID NO: 2)** (hereinafter, abbreviated as peptide A) acetate was weighed in an eggplant-type flask, and 120 g of water for injection was added to dissolve it completely. To this was added 975 g of a lactic acid-glycolic acid copolymer (lactic acid•glycolic acid compositional ratio = 75:25, Mw = about 10,400, Mn = about 4,100, Mw/Mn = 2.5 (value measured by GPC method in Reference Example 5 (value measured using standard substance C))) dissolved in 1600 g of dichloromethane, and this was stirred and emulsified with an autominimixer at about 5800 rpm for 10 minutes to obtain a W/O emulsion. This W/O emulsion was cooled to about 19°C, poured into 200L of a 0.1% (w/w) aqueous polyvinyl alcohol (EG-40, manufactured by The Nippon Synthetic Chemical Industry Co., Ltd.) solution which had been regulated at about 19°C in advance, and stirred and emulsified at about 7000 rpm using HOMOMIC LINE FLOW (manufactured by Tokushu Kika Kogyo Co., Ltd.) to obtain a W/O/W emulsion. This

W/O/W emulsion was stirred at room temperature at about 2500 rpm for 3 hours and dichloromethane was volatilized or diffused into an outer aqueous phase to solidify an oil phase. After passed through a sieve having an opening of 75 μm, a microcapsule was continuously settled with a centrifuge at about 2000 rpm and collected. The collected microcapsule was dispersed in a small amount of distilled water, and passed through a sieve having an opening of 90 μm, and 174.5 g of mannitol was added to dissolve it. This was lyophilized to obtain a microcapsule powder (hereinafter, MC#1). A content of the peptide A was 8.5%.